A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REVOLVE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 30 Nov 2017 This trial has been completed in Spain
    • 19 Oct 2017 According to a company media release, Celgene has decided to stop the REVOLVE and SUSTAIN trials following an October recommendation of the Data Monitoring Committee, which assessed overall benefit/risk during a recent interim futility analysis.
    • 19 Oct 2017 Status changed from recruiting to discontinued, according to a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top